According to filings with the U.S. Securities and Exchange Commission, Element Biosciences has raised $175,000,000.00 in new Series E funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Samsung Electronics.

About Element Biosciences
Element Biosciences is a biotechnology company focused on making high-quality sequencing and multiomics more accessible and affordable. Its website describes the company as opening the world of biology to new possibilities and highlights platforms designed for high-quality, affordable sequencing and multiomics research. The companys flagship offerings include AVITI, a sequencing platform, and AVITI24, which supports spatial and single-cell multiomics with subcellular co-detection of RNA, protein, and morphology on one integrated system. Element Biosciences also emphasizes that its technologies are built to let researchers directly profile complex biological systems rapidly and without library preparation. Founded and led by industry veterans, the company presents itself as a challenger in the genomics market, aiming to advance biological research by lowering the cost barrier to sophisticated sequencing.

To learn more, visit https://www.elementbiosciences.com/
Linkedin: https://www.linkedin.com/company/elembio/

Contact:
Molly He, Chief Executive Officer
https://www.linkedin.com/in/molly-he-2243731/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.